Tina Miller, APRN
Adult Health · Millington, TNNPI 1407195159
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 396 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,667 and has fallen 89.3% since, to $286 in 2025. Among adult health clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$923
- Pfizer$694
- AstraZeneca$371
- UCB, Inc.$364
- Amneal Pharmaceuticals LLC$278
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $1,420 |
| Novartis | 56 | $923 |
| Pfizer | 67 | $694 |
| AstraZeneca(2 entities) | 17 | $371 |
| UCB, Inc. | 13 | $364 |
| Amneal Pharmaceuticals LLC | 22 | $278 |
| SK Life Science, Inc. | 11 | $251 |
| Neurocrine Biosciences, Inc. | 11 | $237 |
| Acadia Pharmaceuticals Inc | 12 | $232 |
| Argenx US, Inc. | 13 | $230 |
| Biogen | 11 | $213 |
| Bristol Myers Squibb | 10 | $183 |
| Lundbeck LLC | 11 | $173 |
| Eisai Inc. | 7 | $130 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $129 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Teva Pharmaceuticals USA, Inc. | 4 | $88 |
| Amgen(2 entities) | 4 | $66 |
| Lilly USA, LLC | 2 | $37 |
| Avion Pharmaceuticals | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Adamas Pharmaceuticals, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
How this compares
$6,381 in reported general payments places this provider in the 90th percentile of 352 adult health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 11 | $105,416 |
| Nurtec OdtRimegepant Sulfate | 31 | $57,864 |
| Emgality PenGalcanezumab-Gnlm | 54 | $37,098 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $35,112 |
| UbrelvyUbrogepant | 28 | $34,905 |
| EliquisApixaban | 40 | $33,689 |
| QuliptaAtogepant | 13 | $13,571 |
| Levetiracetam | 370 | $12,508 |
| Memantine Hcl | 237 | $6,728 |
| Galantamine Hbr | 95 | $6,714 |
| Droxidopa | 13 | $5,517 |
| Lacosamide | 52 | $4,005 |
| Carbamazepine | 51 | $4,005 |
| Donepezil Hcl | 357 | $3,372 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 78 | $3,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $213 | $105,41611 claims |
| PfizerNurtec Odt, Eliquis | $694 | $91,55371 claims |
| AbbVieUbrelvy, Qulipta | $1,420 | $48,47641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 adult health providers in Tennessee.
Other adult health in Millington
- Brenda BaxterNashville$246K
- Artangela HenryMemphis$74K
- Luisa LealNashville$49K
- Robbie LeinartKnoxville$48K
- Terrye MastinMemphis$34K
- Marshe TurnerMemphis$21K
- Sonya KnightSevierville$17K
- Emily LeidigBristol$17K
- Tamera PaceNashville$16K
- Jocelyn McGuireClarksville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.